BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novartis AG (NVS), Vectura Group plc (VEC.L) Lung Drugs Face Delay


10/25/2011 7:41:39 AM

Shares in U.K. drug maker Vectura Group PLC (VEC.LN) fell more than 20% Tuesday after its partner Novartis AG (NOVN.VX) reported delays to the U.S. regulatory approval of key lung drug NVA237. Novartis said U.S. regulators have asked for further clinical data on the drug, an inhaled powder for the treatment of chronic obstructive pulmonary disease, a lung condition known as smoker's lung. The delay will also affect Vectura's QVA149, which combines NVA237 with another drug, and is also licensed to Novartis. The delays are a serious blow to Vectura's prospects, particularly in the case of QVA149, which analysts have tipped as a potential blockbuster lung medicine.

Read at Fox News
Read at Reuters
Read at News Release
Read at This Is London [U.K.]

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES